Conferences: ASCP


ASCP 2023

Safety and Efficacy of KarXT in Patients With Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

ASCP 2023

Site-Independent Replication of Clinical Metrics in a Study of KarXT in Subjects With an Acute Exacerbation of Psychosis in Schizophrenia

ASCP 2021

Characterizing the Antipsychotic Activity and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline + Trospium): Primary and Secondary Results From a Phase 2 Placebo-Controlled Trial in Schizophrenia

ASCP 2021

Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole

ASCP 2020

KarXT (a New Mechanism Antipsychotic Based on Xanomeline), Is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results

ASCP 2019

Xanomeline Plus Trospium: A Novel Strategy to Enhance Pro-Muscarinic Efficacy and Mitigate Peripheral Side Effects